Cimoxatone

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 443525672

| IUPAC_name = 3-[[4-[5-(methoxymethyl)-2-oxo-oxazolidin-3-yl]phenoxy]methyl]benzonitrile

| image = Cimoxatone structure.svg

| width = 250

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 73815-11-9

| ATC_prefix = none

| ATC_suffix =

| PubChem = 52542

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 2104092

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 47493

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = V6FT1QJ7VL

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D02581

| C=19 | H=18 | N=2 | O=4

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C19H18N2O4/c1-23-13-18-11-21(19(22)25-18)16-5-7-17(8-6-16)24-12-15-4-2-3-14(9-15)10-20/h2-9,18H,11-13H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = MVVJINIUPYKZHR-UHFFFAOYSA-N

}}

Cimoxatone (MD 780515) is a reversible inhibitor of MAO-A (RIMA).{{cite journal |vauthors=Nair NP, Ahmed SK, Kin NM, West TE |title=Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients |journal=Acta Psychiatr Scand Suppl |volume=386 |pages=28–35 |year=1995 |pmid=7717092 |doi=10.1111/j.1600-0447.1995.tb05921.x|s2cid=9100689 }} It was never marketed.

Cimoxatone has a half-life of 12.4 hours in humans.{{Cite journal |date=1984-03-01 |title=Cimoxatone: pharmacokinetics of various formulations |url=https://link.springer.com/article/10.1007/BF03314342 |journal=InPharma |language=en |volume=427 |issue=1 |pages=6–6 |doi=10.1007/BF03314342 |issn=2230-6056|url-access=subscription }}